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Abstract
Background: Despite considerable efforts within the microarray community for standardising
data format, content and description, microarray technologies present major challenges in
managing, sharing, analysing and re-using the large amount of data generated locally or
internationally. Additionally, it is recognised that inconsistent and low quality experimental
annotation in public data repositories significantly compromises the re-use of microarray data for
meta-analysis. MiMiR, the Microarray data Mining Resource was designed to tackle some of these
limitations and challenges. Here we present new software components and enhancements to the
original infrastructure that increase accessibility, utility and opportunities for large scale mining of
experimental and clinical data.
Results:  A user friendly Online Annotation Tool allows researchers to submit detailed
experimental information via the web at the time of data generation rather than at the time of
publication. This ensures the easy access and high accuracy of meta-data collected. Experiments are
programmatically built in the MiMiR database from the submitted information and details are
systematically curated and further annotated by a team of trained annotators using a new Curation
and Annotation Tool. Clinical information can be annotated and coded with a clinical Data Mapping
Tool within an appropriate ethical framework. Users can visualise experimental annotation, assess
data quality, download and share data via a web-based experiment browser called MiMiR Online.
All requests to access data in MiMiR are routed through a sophisticated middleware security layer
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thereby allowing secure data access and sharing amongst MiMiR registered users prior to
publication. Data in MiMiR can be mined and analysed using the integrated EMAAS open source
analysis web portal or via export of data and meta-data into Rosetta Resolver data analysis package.
Conclusion:  The new MiMiR suite of software enables systematic and effective capture of
extensive experimental and clinical information with the highest MIAME score, and secure data
sharing prior to publication. MiMiR currently contains more than 150 experiments corresponding
to over 3000 hybridisations and supports the Microarray Centre's large microarray user
community and two international consortia. The MiMiR flexible and scalable hardware and
software architecture enables secure warehousing of thousands of datasets, including clinical
studies, from microarray and potentially other -omics technologies.
Background
Microarray technologies have matured rapidly over the
past few years and present major challenges in managing,
sharing, analysing and re-using the large amount of data
generated [1] despite the considerable international
efforts in standardising data format, content and descrip-
tion [2-6]. Vast numbers of microarray experiments are
performed worldwide every year, many of which become
available upon publication via public repositories like
Gene Expression Omnibus http://www.ncbi.nlm.nih.gov/
geo/[7] and ArrayExpress http://www.ebi.ac.uk/arrayex
press[8]. Many microarray databases have been created to
support local communities with various focuses, for
example on species [9]http://rgd.mcw.edu and http://
www.bugs.sgul.ac.uk microarray platform [10,11], dis-
ease [12-14], institutions or research projects [15-18].
There are two major limitations of public repositories and
most microarray databases. First, although most microar-
ray databases are 'MIAME-compliant', i.e. are designed to
capture the MIAME [5] minimal experimental informa-
tion, these standards and guidelines are often not
enforced, leading to variable, often very minimal, levels of
experimental detail stored alongside microarray data.
Because researchers who submit data to public repositor-
ies are ultimately responsible for the completeness, qual-
ity and accuracy of their submission [7], the majority of
data sets in public repositories have insufficient experi-
mental information available in order for the data to be
re-used effectively in a different analysis. A recent study
looking at Affymetrix data in GEO and ArrayExpress iden-
tified that only 38% of the microarray data meets the
quality and format standards necessary for further integra-
tive analysis [1]. Second, the absence of appropriate secu-
rity models in public repositories and many microarray
databases makes it difficult or sometimes impossible to
share data online prior to publication or to securely store
sensitive biological or clinical information that would be
important for meta-analysis. In addition, the effective col-
lection, annotation and mining of detailed information
on clinical samples e.g. patient age at diagnosis, detailed
disease and treatment information, clinical treatment fol-
low up and outcome data, is particularly challenging due
to legal restrictions associated with storing and disclosing
patient and volunteer clinical information (even in an
anonymised way).
MiMiR, the Microarray Data Mining Resource is an inte-
grated platform for microarray data sharing, mining and
analysis that addresses many of these limitations. MiMiR
stores experimental information to a level of detail higher
than that suggested by MIAME using ontologies and nam-
ing conventions [19]. It provides a powerful platform for
large scale data mining and analysis and enables deposi-
tion of data in ArrayExpress on publication. MiMiR was
initially developed to be used within the Microarray Cen-
tre and was not directly accessible to researchers [19].
Here we describe new software components and enhance-
ments of the original infrastructure that allow researchers
to securely submit, access, share and analyse microarray
and meta-data. Specifically, we have created: (i) a re-engi-
neered hardware and software architecture that protects
the MiMiR database integrity and enables secure online
sharing of unpublished and public data amongst regis-
tered users; (ii) a new web based annotation tool allowing
researchers to easily and quickly submit information
about their experiments and samples; (iii) new sophisti-
cated curation and annotation tools which automatically
create annotated experiments in MiMiR and enable in-
house annotators to check it and add ontology terms and
systematic naming conventions; (iv) a clinical Data Map-
ping Tool to securely capture clinical information in a sys-
tematic way within an appropriate ethical framework; (v)
a new user-friendly web interface that is used by research-
ers to visualise extensive experimental annotation, to
download data and quality assessment reports and to
share un-published datasets with collaborators or other
registered users of the system; (vi) a re-engineered MAGE-
ML pipeline for exporting experiments from MiMiR into
the ArrayExpress repository or into the Rosetta Resolver
package for data analysis; (vii) programmatic access to
MiMiR from the new open source microarray data analy-
sis software package EMAAS [20], allowing users to export
selected data and associated meta-data for analysis.BMC Bioinformatics 2008, 9:379 http://www.biomedcentral.com/1471-2105/9/379
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Construction and content
• MiMiR security model and software architecture
In order to support the growing volume of stored data, the
efficient mining capabilities and secure data access by
multiple concurrent users, we modified the original
MiMiR infrastructure and database schema [19]. A three-
tier architecture comprising a data storage layer, an appli-
cation services layer and a user interface layer was
designed and implemented (Figure 1). This layered
approach decouples (i.e. reduces the dependency of) the
various software components from the MiMiR database
which ensures high scalability and a flexible environment
for software and applications development. The web and
any other user-interface layer application servers are
located in the de-militarised zone (DMZ) [21] which is
protected by one firewall. A sophisticated middleware
layer framework, called MiMiR Data Services Architecture
(MDSA), was developed using Enterprise JavaBeans (EJB)
to allow highly secure remote access to the data in MiMiR
via a role/permissions-based security model. A list of reg-
istered users and role-specific permissions is maintained
in the database to identify and grant access rights. All the
client applications are accessible to registered users upon
login with username and password. Clinical information
stored in MiMiR can also be filtered according to ethical
policies before being delivered back to the client or writ-
ten into the clinical part of MiMiR.
• Experimental information capture, curation and 
annotation
MiMiR stores a high level of experimental information
which exceeds that required by the MIAME guidelines
[19]. The experimental annotation process was enhanced
by implementing an online data collection tool to allow
users to easily and quickly submit, via the web, detailed
experimental information. An internal curation and
annotation tool automatically constructs an experimental
model in MiMiR based on information provided, which
can be checked and further annotated by trained staff.
MiMiR online experimental data collection
Experimental information is collected from users at the
time of data generation rather than at the time of publica-
tion. This ensures easy recall, access and high accuracy of
the meta-data provided and recorded. A web application,
built using the Apache/php5/MySQL and Secure Sockets
Layer (SSL) technologies, enable efficient capture and
automatic submission of comprehensive experimental
The three-tier hardware and software architecture of MiMiR comprises a storage layer, an application services layer and an  access/user interface layer (delimited by dashed lines) Figure 1
The three-tier hardware and software architecture of MiMiR comprises a storage layer, an application services 
layer and an access/user interface layer (delimited by dashed lines). The MiMiR backend database is physically pro-
tected by two firewalls (FW) and is only accessible through the middle tier application servers (MDSA) which act as trusted 
middleware service and security gateway. The demilitarised zone (DMZ) sits between the two firewalls. All requests and 
retrieval of data to and from the web servers in the access layer are done in an encrypted format (marked 'https' with shaded 
arrows). MiMiR staff access internal tools for experimental annotation (GUI) using a less secure data transmission.
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information at no cost to Centre staff time. Data collec-
tion is done through successive stages (Additional File 1)
at which a comprehensive set of fields are presented, some
of which are mandatory. Drop-down menus are available
where possible to limit the use of free text and to facilitate
data capture by minimising typing. Additional informa-
tion can also be uploaded, for example Agilent Bioana-
lyser traces or Excel spreadsheets of quality control (QC)
information. The successive stages follow a logical order
and enable customised fields to be presented depending
on choices applied in the previous step (Additional File
2).
Each stage was implemented in a flexible way to enable
the easy capture of diverse experimental designs including
complex pooling and splitting strategies. Data captured
can be saved at any stage with the option to complete the
remaining stages at a later time. Options to duplicate
entries are available, where appropriate, to reduce the
amount of typing for capturing details about multiple
similar samples. The Online Annotation Tool is currently
configured to capture data from gene expression studies
including single-channel (Affymetrix 3', Exon and Gene
arrays) and two-colour (Agilent) arrays, miRNA profiling,
and can, in future, be extended to other microarray appli-
cations such as ChIP-on-chip. A detailed Help menu is
available at each stage with comprehensive examples of
experiment, sample or QC information recorded. The
Online Annotation Tool allows users to rapidly and effi-
ciently submit many experimental and QC details: it takes
less than one hour to complete the entire process for the
majority of experiments submitted to the Centre (involv-
ing up to 50 samples). Large scale experiments (with more
than 200 samples) can be submitted using the Online
Annotation Tool or via a standardised spreadsheet-based
pipeline under development that can be customised for
individual projects and parsed programmatically for stor-
age into MiMiR.
Once all stages of data capture are completed online, the
information provided is automatically checked for incon-
sistencies and missing data and is then ready for internal
curation using the Curation and Annotation tools.
Curation and further annotation of experimental information
The experimental descriptions submitted by researchers
via the Online Annotation Tool are programmatically
extracted and assembled into an experiment by a specially
designed Curation Tool. The Curation Tool is a Java appli-
cation that uses an internal UML (Unified Modelling Lan-
guage) object model to capture all the submitted
information including details on experimental design,
biosources and biosamples descriptions, compounds,
protocols, treatment steps, user details and relevant publi-
cations, as well as the relationships between these entities.
Automatically built experiment information is presented
to annotators in a graphical form (Figure 2a) where nodes
represent entities such as biosources, biosamples, treated
biosamples, labelled extracts, hybridisation cocktails and
scans, while arcs represent the actions required to move
from one entity to another (i.e. treatment steps). MGED
Ontology and NCI Metathesaurus terms are added to sys-
tematically describe certain experimental entities and can
be viewed in the Curation Tool. Following creation of the
experiment object model, the Annotation Tool is used to
further annotate biomaterials and the relationships
between them. The Annotation Tool is a Java application
that displays information pertaining to biomaterials and
hybridisations in a table view, enabling annotators to
inspect subsets of data for consistency and accuracy, and
to edit fields as appropriate (Figure 2b). MGED Ontology
terms can be appended to experimental components
using the existing MGED Ontology Viewer available
through the Annotation Tool. A comprehensive user
guide for the Annotation and Curation tools is available
in Additional File 3.
• Clinical data capture, annotation and link with 
microarray data
Ethical Framework
The storage and analysis of individual clinical and genetic
data derived from human patients and volunteers is
highly sensitive and requires that appropriate policies and
procedures are defined in respect of ethical issues. MiMiR
has been given formal approval to operate within strict
guidelines under the jurisdiction of a Multi-centre
Research Ethics Committee (MREC, Reference: 05/
MREC05/69). The approval covers the handling of ano-
nymised subjects clinical information which is typically
recorded in hospital patient management systems. The
ethical framework that governs the supply of data to the
clinical part of MiMiR, called cMiMiR, and the subsequent
use by researchers is described in Additional File 4 and
Additional Files 5, 6, 7, 8.
Data Mapping Tool
Clinical data is commonly recorded in Access, Excel or
similar databases that are used as routine patient manage-
ment systems or clinical trial-specific databases. We devel-
oped a Data Mapping Tool to translate clinical
information into codified clinical ontology terms and
concepts and to allow for these descriptions to be
imported into MiMiR in a standardised and structured
way. Several coding schemes exist, providing recognised
sets of unique concept identifiers. These include
SNOMED-CT http://www.snomed.org and the Unified
Medical Language Service (UMLS) http://
umlsinfo.nlm.nih.gov. The UMLS was chosen and imple-
mented in MiMiR as it is used by international efforts such
as the National Cancer Institute caBIG™ https://BMC Bioinformatics 2008, 9:379 http://www.biomedcentral.com/1471-2105/9/379
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cabig.nci.nih.gov/ and it can provide access to SNOMED-
CT terms via its knowledge source web site http://
umlsinfo.nlm.nih.gov/. The UMLS API is used to map
each entity in the source data to the corresponding clinical
ontology term and the associated encoded values are then
automatically assigned (Additional File 5). The resulting
encoded record is represented in an XML format and
linked in the database to the corresponding biosamples
and experimental information. A comprehensive user
guide with a detailed practical example showing screen-
shots of the various stages of clinical annotation is availa-
ble in Additional File 9.
• MiMiR Online experiment browser
Detailed sample/treatment information for each experi-
ment can be accessed via MiMiR Online web front end
that communicates with the MiMiR database via the mid-
dleware layer. Registered users can view and access public
datasets in MiMiR and users with appropriate rights for an
experiment (e.g. the owner of a data set) can share un-
published experiments with other registered users of the
system via the interface (Figure 3a). Two international
consortia are currently using MiMiR to centralise and
share un-published datasets (European Rat tools for func-
tional Genomics (EURATools) http://eura
Screen shots of the Curation and Annotation Tools Figure 2
Screen shots of the Curation and Annotation Tools. a: Visualisation using the Curation Tool of experimental informa-
tion submitted online. An object model of the experiment is programmatically built and represented graphically, where nodes 
represent the experiment and biomaterials (organisms with a prefix BS_ and samples with a prefix BSM_), and treatments are 
represented by arcs. Nodes are colour-coded to represent different stages of sample preparation; for example, beige and pink 
nodes correspond to the extracted total RNA and hybridisation cocktail, respectively. The biomaterial information supplied by 
users via the Online Annotation Tool is automatically displayed in the Curation Tool and assigned with MGED Ontology terms 
as indicated by the prefix "MO:" (bottom table views). Where appropriate NCI Metathesaurus terms and accession numbers 
are also automatically assigned and indicated by the "NCI:" prefix. b: Table views of biosample details in the Annotation Tool. 
The table view enables rapid validation of detailed information including sample types, descriptions and names assigned to sam-
ples by users. Double clicking on an item in the table opens a pop-up window (insert) where more detailed ontology informa-
tion can be viewed and edited.BMC Bioinformatics 2008, 9:379 http://www.biomedcentral.com/1471-2105/9/379
Page 6 of 11
(page number not for citation purposes)
Figure 3 (see legend on next page)BMC Bioinformatics 2008, 9:379 http://www.biomedcentral.com/1471-2105/9/379
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tools.csc.mrc.ac.uk and Wellcome Trust Cardiovascular
Functional Genomics consortium).
Upon logging into MiMiR Online, a list of available exper-
iments is displayed and each experiment can be individu-
ally selected to visualise the design, sample and
hybridisation details (Figure 3b). Users can navigate
through the comprehensive experimental information
recorded including factors, biosources, biosamples, treat-
ments, labelled extracts, protocols. Quality control assess-
ments are displayed at several key steps (e.g. total RNA,
labelled extract and scan) to flag potentially problematic
samples that may lead to unreliable data.
The raw data files can be downloaded from several loca-
tions either in bulk (all the files for a single experiment),
by factor group or for single hybridisation. Clicking on the
'Download' icon initiates retrieval of the relevant files
from the database, which are zipped and sent to the web
browser. A processing bar monitors the progress of the
download which typically takes less than 30 seconds per
.CEL file for an Affymetrix U133Plus 2.0 array.
The quality and reliability of each dataset is assessed by
looking at a number of quality assessment (QA) plots and
metrics generated using the BioConductor open source
software framework http://www.bioconductor.com and
the Affymetrix Expression Console™ software http://
www.affymetrix.com that are compiled into a compre-
hensive QA report available for download in pdf format
(Figure 3b). A comprehensive list of pheno-data e.g.
experimental factors, biological and technical variables,
can also be downloaded and saved in the appropriate for-
mat suitable for import into both open source (Biocon-
ductor) or proprietary (Partek.®) software. This can be
extremely useful to analyse systematic errors (e.g. techni-
cal batch effect) alongside studied biological effects.
• Data Analysis using EMAAS
EMAAS (Extensible Micro Array Analysis System) is a new
web e-support application developed for microarray data
analysis http://www.emaas.org. EMAAS utilizes grid tech-
nologies to perform analysis tasks, programmatically call-
ing analysis packages such as R-BioConductor and the
Affymetrix Power Tools http://www.affymetrix.com.
EMAAS also uses web services to various online facilities
such as DAVID [22], CELSIUS [23] and GeneCards [24].
MiMiR registered users can inspect MiMiR experiments
and associated information from the EMAAS-MiMiR inte-
grated interface and can select specific data files and asso-
ciated meta-data to be imported into EMAAS for analysis
(Figure 4). The MiMiR middleware is used by EMAAS to
securely access the appropriate experimental information,
using Java Server Pages (JSPs) and Servlets. EMAAS is cur-
rently being used to perform data quality assessment, pre-
processing, statistical analysis and functional enrichment
analysis of Affymetrix 3' and Exon/Gene ST arrays, with
scope to add further functionality for other platforms such
as Illumina, Agilent and Codelink arrays [20].
• MAGE-ML export pipelines to ArrayExpress and Resolver
Data in MiMiR is sent to ArrayExpress upon publication
and the original ArrayExpress export pipeline has been re-
engineered into a more generic tool. A model-driven
approach was adopted, whereby a local UML model was
designed to represent all experimental meta-data that is
required for a valid MAGE-ML submission to ArrayExpress
or to the Resolver analysis package. Two sets of Java classes
are created to first interrogate the MiMiR/middleware
layer and extract data elements, and to then populate a
MAGEstk/Java data model to generate a MAGE-ML (xml)
file. The ArrayExpress validation toolkit http://
www.ebi.ac.uk/~ele/ext/submitter.html#val is incorpo-
rated into the MAGE-ML building process to provide auto-
mated validation of MAGE-ML files generated for export
to the relevant system. A total of 24 experiments (corre-
sponding to 730 whole genome arrays) have been submit-
ted to ArrayExpress to date and all the experiment
annotations are of the highest quality, as confirmed by the
highest MIAME score [8] assigned by ArrayExpress.
Screen shots of MiMiR Online Figure 3 (see previous page)
Screen shots of MiMiR Online. a: Screen shot of MiMiR Online showing the data sharing functionality. b: Screen shot of 
MiMiR Online showing the left hand tree view icons for navigation and the right hand panel showing the Experiment Details of 
a public experiment in MiMiR. Several experiments can be opened simultaneously and users can toggle between them using the 
top panel of tabs. Information including the study description, number of biosources (organisms), biosamples and hybridisations 
performed, chip type(s) used, private/public status, ArrayExpress accession number and date of public release (if relevant), as 
well as the active PubMed link if the experiment has been published, can be accessed. MGED Ontology terms are used system-
atically e.g. Category MO:PerturbationalDesign, Value MO:compound_treatment_design) and experimental factors (e.g. Cate-
gory MO:compound, Value H2O2_-0.04). The tree view also gives access to information on the Biomaterials i.e. Biosources 
(whole organisms), Biosamples (material derived from the biosources) and the consecutive treatment steps generating the 
labelled extract to be hybridised on arrays. Different icons are used in the tree to visually facilitate navigation between the dif-
ferent procedure stages.BMC Bioinformatics 2008, 9:379 http://www.biomedcentral.com/1471-2105/9/379
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Utility and discussion
It is recognised that inconsistent and low quality experi-
mental annotation in public data repository significantly
compromises the re-use of microarray data for meta-anal-
ysis [1,23]. MiMiR was designed to overcome this major
limitation. Users can submit experimental information in
an easy, fast and secure way via the web. The meta-data is
collected and stored in MiMiR at the time of data genera-
tion rather than at the point of publication and submis-
sion to ArrayExpress or GEO, which can take up to several
years. As a result, MiMiR captures more accurate and com-
prehensive experiment information than public repositor-
ies and most other microarray databases, and therefore
provides rich experimental details often required for data
mining and cross-experiment re-analysis. The experimen-
tal annotation process is efficiently performed by pro-
grammatically building the experiment structure from the
submitted information and automatically populating
over 60 percent of the required fields. This is recognised as
a major advantage and other systems are looking at
improving the performance and speed of sample annota-
tion [25].
Data is centralised in MiMiR in a highly secure way ena-
bling researchers to share data prior to publication: this is
particularly useful for the national and international con-
sortia that MiMiR supports. MiMiR is compliant with
MAGE and uses MAGE-ML for data exchange with other
MAGE databases (e.g. ArrayExpress and Resolver) rather
than the simplified MAGE-TAB format [26].
MiMiR is fully integrated with the Rosetta Resolver analy-
sis package and experimental information is automati-
cally built in Resolver from annotations stored in MiMiR.
Screen shots of the MiMiR-EMAAS interface, showing a guest user viewing and selecting data and meta-data from a MiMiR  experiment to export into EMAAS for analysis Figure 4
Screen shots of the MiMiR-EMAAS interface, showing a guest user viewing and selecting data and meta-data 
from a MiMiR experiment to export into EMAAS for analysis.BMC Bioinformatics 2008, 9:379 http://www.biomedcentral.com/1471-2105/9/379
Page 9 of 11
(page number not for citation purposes)
Analysis of MiMiR data can also be done using the freely
available EMAAS portal [20]. The EMAAS user base is
growing very rapidly and the system is continuously being
updated with latest analysis algorithms to support new
chip types and applications.
It is well known that molecular signatures derived from
microarray clinical studies can be unstable and highly
dependant on the selection of patients used in the training
set [27]. Michiels et al. for example, found that five of the
seven largest published studies addressing cancer progno-
sis did not classify patients better than chance [28]. Good
validation of prognostic or predictive gene expression pro-
files requires large patient cohort and the clinical part of
MiMiR could be used as a platform to build centralised
data sets for this purpose.
MiMiR stores raw unprocessed microarray data like in
GEO and ArrayExpress in order to maximise the long term
value of datasets and enable processing and re-analysis of
data. However normalisation is necessary in order to mine
data across different experiments and we are planning to
develop a dynamic normalisation pipeline to allow such
comparisons. We also envisage to develop standard anal-
ysis pipelines to generate lists of differentially expressed
genes that will be made available for mining, querying
and further analysis. Query and search functionalities will
be implemented in the system to interrogate and retrieve
datasets of interest for example by species, tissue or array
type.
Conclusion
MiMiR is a mature microarray data warehouse containing
over 3000 arrays worth of data for mining and analysis
and supports over 200 research groups, including two
international consortia. MiMiR is not a new microarray
public repository but it provides a secure environment for
collection, capture, consistent annotation, visualisation
and dissemination of data to our large user community
and collaborators. The clinical part of MiMiR also repre-
sents a unique resource for clinicians and researchers to
effectively share, mine and analyse clinical information
and large scale molecular profiling data within an ethi-
cally approved environment. Analysis of MiMiR data is
enabled through integration with commercial and free-
ware analysis packages and will be enhanced by addi-
tional normalisation and analysis pipelines. MiMiR is a
powerful, scalable and flexible resource that can poten-
tially be extended to new data modalities like next gener-
ation sequencing data for which similar ethical, social and
clinical constrains apply and are beginning to be
addressed by the research and clinical communities
[29,30].
Availability and requirements
MiMiR Online and the Online Annotation Tool can be
accessed from the Microarray Centre-MiMiR User Centre
web site http://microarray.csc.mrc.ac.uk. The code for the
Curation and Annotation tools as well as the MAGE-ML
export pipeline and the Data Mapping Tool can be made
available on request. A comprehensive user manual for
the Annotation and Curation tools is also available from
the Microarray Centre web site. The tools have been opti-
mised for Windows environment and, although untested,
could be used with other operating systems.
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Additional material
Additional File 1
Stages of experimental information collection using the Online Annota-
tion Tool. Experiment and sample information are collected using a series 
of online forms starting with an overview of the experiment (stages 1–4), 
followed by detailed information pertaining to organisms, arrays and sam-
ples (stages 5–7). Specific details of protocols used (stages 8–9) and 
Quality Control parameters (stages 10–12) are also collected. There are 
two key decision stages (stages 5 and 9) which determine the fields pre-
sented to users in subsequent stages.
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